Our health data can significantly contribute to better disease prevention, early diagnosis in a safe and secure way. SimCardioTest, led by Inria, gathers ten international partners including VPHi, and is funded by the European Commission. The aim of SimCardioTest is to demonstrate the feasibility, efficacy and benefits of in-silico trials for disease.
SimCardioTest is developing credible computer modelling and simulation approaches for testing cardiac drugs and devices. These in-silico tests will be accessible on a newly created secure and standardised cloud-based platform. Specific computational models will be designed for three uses cases concerning the treatment of pathologies associated to ischaemia, atrial fibrillation, and heart failure. The first use case Pacing devices and leads is designed by University of Bordeaux, together with Microport, the second one The Left atrial appendage occluder is developed at Universitat Pompeu Fabra with Boston Scientific and the last one Drugs, efficacy and toxicity is led by Universitat Politècnica de València with ExactCure. Simula and Insilicotrials are also focusing on the standardisation of these models.
…. More to come!
The success of such trials will prove that in-silico trials can replace some of the invasive aspects of clinical trials, reduce the number of animal tests and provide new biomarkers to improve the accuracy in prediction from clinical trials.